SCHEDULE 13G/A: Morgan Stanley Reduces Stake in Syndax Pharmaceuticals Below 5%

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have filed an amended Schedule 13G indicating they are no longer beneficial owners of more than five percent of Syndax Pharmaceuticals Inc.'s common stock.

Summary

• Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have filed an Amendment No. 1 to Schedule 13G concerning their beneficial ownership of Syndax Pharmaceuticals Inc. common stock.
• The filing indicates that as of March 31, 2025, Morgan Stanley has ceased to be the beneficial owner of more than five percent of Syndax Pharmaceuticals Inc.'s common stock.
• Morgan Stanley's aggregate beneficial ownership is now 2,040,013 shares, representing 2.4% of the class.
• Morgan Stanley & Co. LLC's aggregate beneficial ownership is 213,174 shares, representing 0.2% of the class.
• The securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory filing disclosing a change in beneficial ownership, and as such, it carries a neutral sentiment.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Syndax Pharmaceuticals Inc.'s future outlook.

Management Comments

• Chris O'Hara, Authorized Signatory for Morgan Stanley and Morgan Stanley & Co. LLC, certified that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing represents a routine disclosure of a change in institutional ownership, which is a common occurrence in the financial markets. It does not provide specific insights into broader industry trends within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The reduction in Morgan Stanley's stake below the 5% threshold could be interpreted by the market as a signal, potentially influencing investor sentiment and the company's share price.

Key Dates

Keywords

Syndax Pharmaceuticals, Morgan Stanley, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Stake Reduction, Common Stock